NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies
Completed
- Conditions
- Chronic Myeloid LeukemiaHealthyHematologic NeoplasmLymphoma
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 75
- Registration Number
- NCT00001432
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers
Phase 1
Completed
- Conditions
- Colorectal NeoplasmHereditary Nonpolyposis
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00001693
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Randomized, Double Blind, Placebo-Controlled, Phase IIB Trial of Ketorolac Mouth Rinse Evaluating the Effect of Cyclooxygenase Inhibition on Oropharyngeal Leukoplakia: Collaborative Study of the NCI, NIDCD and the NIDCR
Phase 2
Completed
- Conditions
- LeukoplakiaPeriodontal Disease
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 57
- Registration Number
- NCT00001698
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer
Phase 1
Completed
- Conditions
- LymphomaMelanomaNeoplasm MetastasisRenal Cell Carcinoma
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00001683
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Studies of Inherited Diseases of Metabolism
Completed
- Conditions
- Multiple Endocrine Neoplasia
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2023-01-20
- Target Recruit Count
- 969
- Registration Number
- NCT00001345
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers
Completed
- Conditions
- Kaposi's SarcomaLeukemiaLymphomaAcquired Immunodeficiency SyndromeHIV InfectionsTumor Virus Infection
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00001560
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Blastomycosis Dermatitidis Infection in Patients Not Infected With HIV and Complications Associated With Blastomycosis Dermatitidis Infection
Completed
- Conditions
- Blastomycosis
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 400
- Registration Number
- NCT00001702
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
The Body's Affect on Vitamin C
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Other: Vitamin C
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2025-05-06
- Target Recruit Count
- 23
- Registration Number
- NCT00001309
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial
Phase 2
Completed
- Conditions
- Neoplasm MetastasisBreast Neoplasm
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 130
- Registration Number
- NCT00001250
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease
Completed
- Conditions
- MelanomaBreast CancerLymphomaOvarian CancerProstate Cancer
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1031
- Registration Number
- NCT00001503
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath